Spark Therapeutics Inc. (ONCE)

102.27
1.48 1.47
NASDAQ : Health Technology
Prev Close 100.79
Open 101.29
Day Low/High 100.81 / 102.36
52 Wk Low/High 34.53 / 114.20
Volume 260.31K
Avg Volume 786.20K
Exchange NASDAQ
Shares Outstanding 37.75M
Market Cap 3.85B
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.

Spark Therapeutics Announces Collaboration With Leading Gene Therapy Center At University Of Massachusetts Medical School

Spark Therapeutics Announces Collaboration With Leading Gene Therapy Center At University Of Massachusetts Medical School

Multi-year collaboration focuses on selecting adeno-associated virus vectors to target debilitating genetic diseases in cells of the retina, liver and central nervous system

Spark Therapeutics Launches Initiative To Improve Access To Genetic Testing For Inherited Retinal Diseases

Spark Therapeutics Launches Initiative To Improve Access To Genetic Testing For Inherited Retinal Diseases

Free Genetic Test Helps Eligible Patients in U.S. Affected by Certain Progressive Retinal Diseases Get Support and Information

Jim Cramer's Top Takeaways: Spark Therapeutics, General Mills, Kellogg, ConAgra, Campbell

Jim Cramer's Top Takeaways: Spark Therapeutics, General Mills, Kellogg, ConAgra, Campbell

Cramer says be prepared to sell the food group because it is getting too difficult to gauge.

Jim Cramer's 'Mad Money' Recap: This Market Has a One-Track Mind

Jim Cramer's 'Mad Money' Recap: This Market Has a One-Track Mind

When the market decides only one thing is working, that makes things treacherous for everyone else,

Spark Therapeutics And Pfizer Announce Updated Data From First Cohort In Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels Of Factor IX Activity

Spark Therapeutics And Pfizer Announce Updated Data From First Cohort In Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels Of Factor IX Activity

First four subjects all with follow up beyond 12 weeks without any need for immunosuppression

13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys

13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys

MIT's Smart 50 list recognizes companies for their combination of innovative technology and effective management, and it includes 13 pharmaceutical and biotech firms this year.

Strong On High Relative Volume: Spark Therapeutics (ONCE)

Strong On High Relative Volume: Spark Therapeutics (ONCE)

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a strong on high relative volume candidate

Spark Therapeutics Announces Publication Of Positive Follow-Up Data From Phase 1 Trial Of Voretigene Neparvovec In The Lancet

Spark Therapeutics Announces Publication Of Positive Follow-Up Data From Phase 1 Trial Of Voretigene Neparvovec In The Lancet

Study provides insight into long-term safety and durability of effect of contralateral-eye administration in subjects with childhood-onset blindness caused by RPE65 mutations

'Mad Money' Lightning Round: You Should Own General Electric

'Mad Money' Lightning Round: You Should Own General Electric

Cramer says you're in good shape with Dominion Resources, but he is avoiding Freeport-McMoRan.

Jim Cramer's 'Mad Money' Recap: What a Relief! This Rally Has Legs

Jim Cramer's 'Mad Money' Recap: What a Relief! This Rally Has Legs

Investors re-evaluated what stocks are actually worth and started buying, Cramer says.

Spark Therapeutics (ONCE) Stock: Weak On High Volume Today

Spark Therapeutics (ONCE) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a weak on high relative volume candidate

Spark Therapeutics (ONCE) Trading With Heavy Volume Before Market Open

Spark Therapeutics (ONCE) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a pre-market mover with heavy volume candidate

TheStreet Quant Rating: D+ (Sell)